TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.
Brief Summary: Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis.


Options:
A: Arm Label: ISV-403; Type: EXPERIMENTAL; Interventions: Drug: ISV-403 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: ISV-403; Assigned to Arm(s): ISV-403 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle
B: Arm Label: Moxifloxacin AF; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5% | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Other: Moxifloxacin AF Vehicle | Intervention Type: DRUG; Name: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%; Assigned to Arm(s): Moxifloxacin AF | Intervention Type: OTHER; Name: Moxifloxacin AF Vehicle; Assigned to Arm(s): Vehicle
C: Arm Label: ISV-403; Type: EXPERIMENTAL; Interventions: Drug: ISV-403 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: ISV-403; Assigned to Arm(s): ISV-403 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle
D: Arm Label: AzaSite; Type: EXPERIMENTAL; Interventions: Drug: AzaSite | Arm Label: Vehicle; Type: SHAM_COMPARATOR; Interventions: Other: Vehicle | Intervention Type: DRUG; Name: AzaSite; Assigned to Arm(s): AzaSite | Intervention Type: OTHER; Name: Vehicle; Assigned to Arm(s): Vehicle

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects With Mild to Moderate Alzheimer's Disease
Brief Summary: The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's Disease. SB-742457 is a new treatment which is thought to increase the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's Disease.


Options:
A: Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: donepezil | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: SB-742457; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aricept (donepezil SR 23 mg) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aricept (donepezil IR 10 mg) | Intervention Type: DRUG; Name: Aricept (donepezil SR 23 mg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aricept (donepezil IR 10 mg); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare whether there is the difference in the effect of insulin therapy by the number of times of insulin injection.


Options:
A: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: dual-action insulin analog; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Insulin infusion with a goal; Assigned to Arm(s): N/A
D: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Masked Comparison of Acular LS Plus Steroid Versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients
Brief Summary: Evaluate if the incidence of sub clinical CME can be significantly reduced by use of peri-operative Acular LS plus Pred Forte when compared with Pred Forte alone in normal cataract patients.


Options:
A: Arm Label: NEVANAC; Type: EXPERIMENTAL; Interventions: Drug: Nepafenac ophthalmic suspension, 0.1% (NEVANAC), Drug: Prednisolone acetate ophthalmic suspension (OMNIPRED) | Arm Label: Nepafenac Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Other: Nepafenac ophthalmic suspension vehicle, Drug: Prednisolone acetate ophthalmic suspension (OMNIPRED) | Intervention Type: DRUG; Name: Nepafenac ophthalmic suspension, 0.1% (NEVANAC); Assigned to Arm(s): NEVANAC | Intervention Type: OTHER; Name: Nepafenac ophthalmic suspension vehicle; Assigned to Arm(s): Nepafenac Vehicle | Intervention Type: DRUG; Name: Prednisolone acetate ophthalmic suspension (OMNIPRED); Assigned to Arm(s): NEVANAC, Nepafenac Vehicle
B: Intervention Type: DRUG; Name: Ketorolac, Prednisolone Acetate; Assigned to Arm(s): N/A
C: Arm Label: NEVANAC; Type: EXPERIMENTAL; Interventions: Drug: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®) | Arm Label: Nepafenac Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nepafenac ophthalmic suspension vehicle | Intervention Type: DRUG; Name: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®); Assigned to Arm(s): NEVANAC | Intervention Type: DRUG; Name: Nepafenac ophthalmic suspension vehicle; Assigned to Arm(s): Nepafenac Vehicle
D: Arm Label: Nepafenac; Type: EXPERIMENTAL; Interventions: Drug: Nepafenac | Arm Label: Ketorolac; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketorolac | Intervention Type: DRUG; Name: Nepafenac; Assigned to Arm(s): Nepafenac | Intervention Type: DRUG; Name: Ketorolac; Assigned to Arm(s): Ketorolac

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon
Brief Summary: The goal of this study was to test whether adalimumab can induce mucosal healing in subjects with moderate to severe ileocolonic Crohn's Disease.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endoscopy | Arm Label: Standard care arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: endoscopy; Assigned to Arm(s): Active arm
C: Arm Label: Double Blind; Type: PLACEBO_COMPARATOR; Interventions: Biological: adalimumab, Biological: placebo | Arm Label: Open Label; Type: OTHER; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Open Label
D: Arm Label: Tight Control Management; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Prednisone, Drug: Azathioprine | Arm Label: Clinically Driven Management; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab, Drug: Prednisone, Drug: Azathioprine | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Clinically Driven Management, Tight Control Management | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Clinically Driven Management, Tight Control Management | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Clinically Driven Management, Tight Control Management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon
Brief Summary: The goal of this study was to test whether adalimumab can induce mucosal healing in subjects with moderate to severe ileocolonic Crohn's Disease.


Options:
A: Arm Label: Double Blind; Type: PLACEBO_COMPARATOR; Interventions: Biological: adalimumab, Biological: placebo | Arm Label: Open Label; Type: OTHER; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Open Label
B: Arm Label: Cohort 1: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cohort 2: Induction; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 3: Induction; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 1: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cohort 2: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 3: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 1: Open Label; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Induction | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 2: Induction | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 3: Induction | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 2: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 3: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 1: Open Label
C: Arm Label: CDP870 400 mg; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): CDP870 400 mg
D: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.
Brief Summary: The primary objective of the study is to compare the efficacy of levosimendan and dobutamine on all-cause mortality in the 180 days following randomization.


Options:
A: Intervention Type: PROCEDURE; Name: angioplasty, transluminal, percutaneous coronary; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: coronary artery bypass; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: thrombolytic therapy; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dobutamine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Tilarginine Acetate Injection intravenous infusion; Assigned to Arm(s): N/A
D: Arm Label: Levosimendan; Type: EXPERIMENTAL; Interventions: Drug: Levosimendan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): Levosimendan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effects of a Water Cure on Gonarthrosis: Randomized Clinical Study Including Water Cure Versus Continuation of the Usual Treatment
Brief Summary: The main objective of this study is to evaluate the therapeutic effect of a thermal treatment on gonarthrosis, with an increase of the number of patients presenting a clinically significant improvement.


Options:
A: Intervention Type: DEVICE; Name: Shoe Insert; Assigned to Arm(s): N/A
B: Arm Label: Health Education Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Arm Label: Usual Medical Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Osteoarthritis Self-Management; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoarthritis Self-Management | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): Health Education Intervention | Intervention Type: BEHAVIORAL; Name: Osteoarthritis Self-Management; Assigned to Arm(s): Osteoarthritis Self-Management
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: thermal cure | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: 3 days access to watering place at 6 months | Intervention Type: DRUG; Name: thermal cure; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 3 days access to watering place at 6 months; Assigned to Arm(s): 2
D: Arm Label: active; Type: ACTIVE_COMPARATOR; Interventions: Device: Wearable pulsed electromagnetic fields | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Wearable pulsed electromagnetic fields | Intervention Type: DEVICE; Name: Wearable pulsed electromagnetic fields; Assigned to Arm(s): active, placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Chagas Cardiomyopathy
Brief Summary: The purpose of this study is to determine effect of cell therapy in patients with severe dilated cardiomyopathy


Options:
A: Arm Label: Experimental: Human (aMBMC); Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) | Arm Label: Placebo:Lactated Ringer's Solution (LRS); Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactated Ringer's Solution | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC); Assigned to Arm(s): Experimental: Human (aMBMC) | Intervention Type: DRUG; Name: Lactated Ringer's Solution; Assigned to Arm(s): Placebo:Lactated Ringer's Solution (LRS)
B: Arm Label: Stem Cell therapy; Type: EXPERIMENTAL; Interventions: Procedure: Stem cell, Drug: Filgrastime (G-CSF) | Arm Label: Standart therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standart therapy | Intervention Type: PROCEDURE; Name: Stem cell; Assigned to Arm(s): Stem Cell therapy | Intervention Type: DRUG; Name: Filgrastime (G-CSF); Assigned to Arm(s): Stem Cell therapy | Intervention Type: DRUG; Name: Standart therapy; Assigned to Arm(s): Standart therapy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous human mesenchymal cells (hMSCs) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous human bone marrow cells (hBMCs) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Autologous human mesenchymal cells (hMSCs); Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Autologous human bone marrow cells (hBMCs); Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Intracoronary; Type: EXPERIMENTAL; Interventions: Other: Bone marrow derived progenitor cells or placebo infusion | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo infusion | Intervention Type: OTHER; Name: Bone marrow derived progenitor cells or placebo infusion; Assigned to Arm(s): Intracoronary | Intervention Type: OTHER; Name: Placebo infusion; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With B-cell Chronic Lymphocytic Leukemia Who Have Failed Fludarabine and Alemtuzumab
Brief Summary: The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab.


Options:
A: Arm Label: ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: ofatumumab | Intervention Type: DRUG; Name: ofatumumab; Assigned to Arm(s): ofatumumab
B: Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: rituximab arm; Type: EXPERIMENTAL; Interventions: Biological: Rituximab | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): rituximab arm
C: Arm Label: Idelalisib + rituximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idelalisib, Drug: Rituximab | Arm Label: Placebo + rituximab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab, Drug: Placebo to match idelalisib | Intervention Type: DRUG; Name: Idelalisib; Assigned to Arm(s): Idelalisib + rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Idelalisib + rituximab, Placebo + rituximab | Intervention Type: DRUG; Name: Placebo to match idelalisib; Assigned to Arm(s): Placebo + rituximab
D: Arm Label: Bendamustine + GA101 + CAL-101; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: GA101, Drug: CAL-101 | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + GA101 + CAL-101 | Intervention Type: DRUG; Name: GA101; Assigned to Arm(s): Bendamustine + GA101 + CAL-101 | Intervention Type: DRUG; Name: CAL-101; Assigned to Arm(s): Bendamustine + GA101 + CAL-101

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With B-cell Chronic Lymphocytic Leukemia Who Have Failed Fludarabine and Alemtuzumab
Brief Summary: The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab.


Options:
A: Arm Label: Active Comparator 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab 500mg, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Active Comparator 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab 1000mg, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Ofatumumab 500mg; Assigned to Arm(s): Active Comparator 1 | Intervention Type: DRUG; Name: Ofatumumab 1000mg; Assigned to Arm(s): Active Comparator 2 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Active Comparator 1, Active Comparator 2 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Active Comparator 1, Active Comparator 2
B: Arm Label: ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: ofatumumab | Intervention Type: DRUG; Name: ofatumumab; Assigned to Arm(s): ofatumumab
C: Arm Label: ofatumumab + chlorambucil; Type: EXPERIMENTAL; Interventions: Drug: chlorambucil, tablets, Drug: ofatumumab (GSK1841157) infusion | Arm Label: chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: chlorambucil, tablets | Intervention Type: DRUG; Name: chlorambucil, tablets; Assigned to Arm(s): chlorambucil, ofatumumab + chlorambucil | Intervention Type: DRUG; Name: ofatumumab (GSK1841157) infusion; Assigned to Arm(s): ofatumumab + chlorambucil
D: Arm Label: Fludarabine+Cyclophosphamide+Rituximab (FCR); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Arm Label: Fludarabine+Cyclophosphamide (FC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Trial to Increase t-PA Use in Stroke Treatment
Brief Summary: The purpose of this study is to evaluate a standardized, system-based, barrier assessment and interactive educational intervention to increase appropriate t-PA use for stroke.


Options:
A: Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Quality Initiative in Rectal Cancer (QIRC) strategy; Assigned to Arm(s): N/A
C: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Barrier assessment / interactive educational intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Barrier assessment / interactive educational intervention; Assigned to Arm(s): Intervention

Answer: D